SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – NEW INDICATIONS OF TUOYI® AND JUNSHIDA HAVE BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 7 December 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that two new indications of the Company's product Toripalimab Injection (trade name: TUOYI®, product code: JS001), and Ongericimab Injection (trade name: JUNSHIDA (君適達®), product code: JS002) were successfully included in Category B of the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (Year 2025) (the "**NRDL**"). The new edition of the NRDL will officially come into effect on 1 January 2026.

As of the date of this announcement, the Company's four commercialized products, namely TUOYI®, Adalimumab Injection (trade name: JUNMAIKANG (君邁康®), product code: UBP1211), Deuremidevir Hydrobromide Tablets (trade name: MINDEWEI (民得維®), product code: VV116/JT001), and JUNSHIDA, have all been included in the NRDL. All 12 indications of TUOYI® approved for marketing in Chinese Mainland have been included in the NRDL, which is the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of renal cancer, triple-negative breast cancer ("**TNBC**") and melanoma. JUNSHIDA, being included in the NRDL for the first time, is the only domestic PCSK9-targeted drug in the new edition of the NRDL for statin-intolerant patients.

ABOUT TUOYI®

Drug name: Toripalimab Injection
Classification of registration: Therapeutic biological product
Class of drug: Antineoplastic drug and immune modulator – monoclonal antibody and antibody drug conjugates -PD-1/PD-L1 inhibitor
Class of medical insurance: Category B
Dosage form: Injection

Indications: 1. Treatment for unresectable or metastatic melanoma after failure of standard systemic therapy; 2. First-line treatment of unresectable or metastatic melanoma; 3. Treatment for locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; 4. Treatment for recurrent/metastatic nasopharyngeal carcinoma ("**NPC**") after failure of at least two lines of prior systemic therapy; 5. In combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC; 6. In combination with paclitaxel and cisplatin as the first-line treatment for patients with unresectable locally advanced/ recurrent or metastatic esophageal squamous cell carcinoma ("**ESCC**"); 7. In combination with pemetrexed and platinum as the first-line treatment in epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK) mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer ("**NSCLC**"); 8. In combination with platinum-containing chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB NSCLC; 9. In combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma; 10. In combination with etoposidein plus platinum for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC); 11. In combination with paclitaxel for injection (albumin-bound) for the first-line treatment of recurrent or metastatic TNBC with a well-validated test to evaluate PD-L1 positive (CPS ≥ 1); 12. In combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma patients; Items 2 and 12 are new indications included in the NRDL.
Validity period: From 1 January 2026 to 31 December 2027

Toripalimab injection is the first domestic anti-PD-1 monoclonal antibody approved for marketing in China, and has won the "Chinese Patent Gold Award (中國專利金獎)", the top award in China's patent field. In December 2020, toripalimab injection was successfully negotiated into the NRDL (2020 edition) for the first time. As of the date of this announcement, all of its 12 indications approved in Chinese Mainland have been included in the NRDL, which is the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of renal cancer, TNBC and melanoma. Three indications of toripalimab for the treatment of advanced NPC and ESCC have been approved in Hong Kong SAR, China.

In terms of international layout, toripalimab has been approved for marketing in the United States, the European Union, India, the United Kingdom, Jordan, Australia, Singapore, the United Arab Emirates, Kuwait, Pakistan, Canada and other countries and regions, and is also under review for marketing in various countries and regions worldwide.

ABOUT JUNSHIDA

Drug name: Ongericimab Injection
Classification of registration: Therapeutic biological product
Class of drug: Cardiovascular system – lipid-regulating drugs
Class of medical insurance: Category B
Dosage form: Injection

Indications: Treatment for adult patients with primary hypercholesterolemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia, who fail to achieve low-density lipoprotein cholesterol (LDL-C) goals after receiving moderate or higher doses of statins treatment; or alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated. Validity period: From 1 January 2026 to 31 December 2027

Ongericimab injection is a recombinant humanized anti-PCSK9 monoclonal antibody injection independently developed by the Company. It was approved for marketing by the National Medical Products Administration in October 2024. As of the date of this announcement, ongericimab injection has been approved for three indications in Chinese mainland for the treatment of: 1) adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia; 2) adult patients with HeFH; 3) alone or in combination with ezetimibe, in adult patients with non-familial hypercholesterolemia and mixed dyslipidemia who are statin-intolerant or statins contraindicated. The approved specifications are 150 mg (1 ml) in a single dose (pre-filled syringe), 150 mg (1 ml) in a single dose (pre-filled autosyringe). In December 2025, ongericimab injection was successfully negotiated into the new edition of the NRDL for the first time and is the only domestic PCSK9-targeted drug in the NRDL for statin-intolerant patients.

In October 2023, the Company signed an agreement with Chongqing Bochuang Pharmaceuticals Co., Ltd.* (重慶博創醫藥有限公司) ("**Bochuang Pharmaceuticals**"), pursuant to which the Company granted Bochuang Pharmaceuticals an exclusive license to conduct research and development on, manufacture and commercialize, ongericimab for the licensed purposes and within Chinese Mainland. Bochuang Pharmaceuticals will be responsible for the subsequent commercialization of ongericimab in Chinese Mainland and will make corresponding milestone payments and sales commissions to the Company.

IMPACTS ON THE COMPANY AND RISK WARNING

The inclusion of the new indications of TUOYI® and JUNSHIDA in the NRDL demonstrated the National Healthcare Security Administration's (the "**NHSA**") recognition of the clinical value, benefit to patients and novelty of the above drug, highlighting the state's emphasis on and support for the R&D and industrialization of drugs by local innovative pharmaceutical enterprises.

All commercialized products of the Company have been included in the NRDL, which will help to further improve the affordability and accessibility for patients, and will be conducive to further promoting the marketing of commercialized products and enhancing the sales scale, thus having a positive impact on the long-term development of the Company. The Company will actively work with relevant parties to implement the related medical insurance and reimbursement policies, promote the accessibility of the drug to hospitals with continuous efforts, and expand the coverage of core markets and other markets, with a view to constantly enhancing the accessibility of medicines to patients. Details of medical insurance reimbursement and other relevant information shall be subject to the information published by the NHSA and other relevant government departments. Investors are advised to make cautious decisions and pay careful attention to investment risks.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 7 December 2025

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purpose only*